



04 June 2015

**FDA MEMORANDUM CIRCULAR**  
No. **2015-005**

**TO: ALL DRUG DISTRIBUTOR-WHOLESALEERS, DRUGSTORES/PHARMACY/BOTICA AND OTHER SIMILAR OUTLETS, AND RETAIL OUTLET FOR NON-PRESCRIPTION DRUGS**

**SUBJECT: Reiteration to Procure Drug Products from FDA-licensed Marketing Authorization Holders (MAHs)**

In order to promote and protect the health of the Filipino people and to ensure the quality, safety, and efficacy of health products, the Food and Drug Administration (FDA) continually conducts its post-marketing surveillance (PMS) by monitoring unregistered, illegally diverted, and counterfeit drug products in the Philippine market. The FDA informs the public on products that pose potential danger or injury to the public through the issuance of an FDA Advisory.

Recently, FDA has observed an increasing trend in the number of unregistered, illegally diverted and counterfeit drug products with continuing reports on their availability in the market. This increasing trend denotes the proliferation of these products which pose health risks to the public.


In light of this, FDA hereby reiterates that all drug distributor-wholesalers, drugstores/pharmacy/botica and other similar outlets, and retail outlet for non-prescription drugs (RONPD) must be vigilant in the procurement of drug products that they make available to the public. The said establishments should:

- (1) Check the authenticity of the Certificate of Product Registration (CPR) of the products they procure and the License to Operate (LTO) of their supplier, which can be verified with FDA;
- (2) Demand official receipts;
- (3) Check for the latest FDA Advisory(ies)

Please be reminded that as per Book II, Section I of the Implementing Rules and Regulation (IRR) of Republic Act 9711, all drug products that are made available to the public must have proper authorization from the FDA prior to marketing. Whereas, Section 4 of Republic Act 8203 prohibits *the manufacture, sale, offering for sale, donation, distribution, trafficking, brokering, exportation, importation, or possession of counterfeit drugs.*

Further, for suspected unregistered, illegally diverted, and counterfeit drug products, or for any information related to the continuous sale or distribution, you must report immediately to FDA either through email via [report@fda.gov.ph](mailto:report@fda.gov.ph) or phone call at (02) 807-8275. For any suspected adverse drug reaction (ADR) as a result of the use of such products, please report immediately to FDA through our website: [www.fda.gov.ph](http://www.fda.gov.ph). Look for the ADR tab and fill out all the required fields.

For verification and updates, please check the FDA website via [www.fda.gov.ph](http://www.fda.gov.ph). For more information and inquiries, please email us at [info@fda.gov.ph](mailto:info@fda.gov.ph).

  
**JANETTE P. LORETO-GARIN, MD, MBA-H**  
Secretary of Health  
Acting Director General

DTN:20150521163852

<sup>1</sup> Pursuant to DPO 2015-1845